Editor’s note: The Myasthenia Gravis News team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Many people with myasthenia gravis (MG) experience unusual fatigue, including those with pure ocular disease or with…
Editor’s note: The Myasthenia Gravis News team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read stories from the conference. Myasthenia gravis (MG) patients who test negative for the presence of the most common MG self-reactive antibodies (autoantibodies) more…
Editor’s note: The Myasthenia Gravis News team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Janssen’s experimental therapy nipocalimab (M281) safely, rapidly, and effectively reduced disease severity in adults with generalized…
Editor’s note: The Myasthenia Gravis News team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. People with myasthenia gravis (MG) have used a patient-led analysis to document and share with healthcare professionals their…
More than half of the people with rare diseases and their caregivers, asked in a survey, were undecided or less than willing to be vaccinated for COVID-19 if a vaccine was approved under emergency use authorization instead of the routine process, the EveryLife Foundation for Rare Disease reports. These findings…
Editor’s note: The Myasthenia Gravis News team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference Soliris (eculizumab), a treatment for people with generalized myasthenia gravis…
Editor’s note: The Myasthenia Gravis News team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference Rituximab, an approved immunosuppressive treatment for certain cancers and autoimmune conditions, effectively eases disease severity and prevents…
The EveryLife Foundation for Rare Diseases is accepting applications for a scholarship program that aims to help adults with a rare disease pursue personal goals through training and education. For a second year, the #RAREis Scholarship Fund — supported by Horizon Therapeutics – will award 35 one-time scholarships, each…
Blood levels of two pro-inflammatory subsets of immune T-cells are abnormally low in people with myasthenia gravis (MG) who have antibodies against the acetylcholine receptor (AChR), a study shows. The reduced levels of these cells were associated with their retention in a patient’s thymus — whose removal is a…
Greater reductions in the levels of antibodies against the acetylcholine receptor (AChR) within the first three months after immunosuppressive treatment in people with myasthenia gravis (MG) are associated with better one-year post-therapy outcomes, a study shows. These findings suggest that measuring anti-AChR antibodies shortly after the start of such therapy…
Get regular updates to your inbox.